Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: Evidence from a population-based study

Journal of the American College of Cardiology

Volumn 32, Issue 7, 1998, Pages 1839-1844

  Luchner, Andreas ^a   Burnett Jr , John C ^b   Jougasaki, Michihisa ^b   Hense, Hans Werner ^c,d   Riegger, Günter A j ^a   Schunkert, Heribert ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b MAYO CLINIC   (United States)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP;

ADULT; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; DRUG EFFECT; FEMALE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS REGULATION; TISSUE DISTRIBUTION;

ADRENERGIC BETA-ANTAGONISTS; AGED; ATRIAL NATRIURETIC FACTOR; DRUG INTERACTIONS; FEMALE; HEART; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SYMPATHETIC NERVOUS SYSTEM;

EID: 0032420652     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00478-1     Document Type: Article

References (34)

1. The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch Intern Med. 153:1993;154-183.
2. Pepine C., Cohn P., Deedwania P., et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life. Circulation. 90:1994;762-768.
3. Waagstein F., Hjalmarson A., Varnauskas E., Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J. 37:1975;1022-1036.
4. Waagstein F., Bristow M., Swedberg K., et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 342:1993;1441-1446.
5. Eichhorn E., Heesch C., Barnett J., et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy a randomized, double-blind, placebo-controlled study . J Am Coll Cardiol. 24:1994;1310-1320.
6. Fisher M., Gotlieb S., Plotnick G., et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease a randomized trial . J Am Coll Cardiol. 23:1994;943-950.
7. Olsen S., Gilbert E., Anderson J., et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure a double-blind randomized study . J Am Coll Cardiol. 25:1994;1225-1231.
8. Swedberg K., Hjalmarson A., Waagstein F., Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet. 1:1979;1374-1376.
9. Packer M., Bristow M., Cohn J., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. NEJM. 334:1996;1349-1355.
10. Christensen G., Ilbekk A., Kiil F. Release of atrial natriuretic factor during infusion of isoproterenol and angiotensin II. Am J Physiol. 257:1989;R896-R900.
11. Christensen G., Aksnes G., Ilebekk A., Kiil F. Release of atrial natriuretic factor during selective cardiac α- and β-adrenergic stimulation, intracoronary Ca infusion, and aortic constriction in pigs. Circ Res. 68:1991;638-644.
12. Nakaoka H., Kitahara Y., Amano M., et al. Effect of β-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension. Hypertension. 10:1987;221-225.
13. Hama J., Nagata S., Takenaka T., et al. Atrial natriuretic peptide and antihypertensive action due to beta blockade in essential hypertensive patients. Angiology. 46:1995;511-516.
14. Keil U., Stieber J., Döring A., et al. The cardiovascular risk factor profile in the study area Augsburg results from the first MONICA survey 1985/85 . Acta Med Scand. 728:1988;119-128.
15. Sahn D., De Maria A., Kisslo J., Weyman A. The committee on M-mode standardization of the American Society of Echocardiography results on a survey of echocardiographic measurements . Circulation. 58:1978;1072-1083.
16. Devereux R., Koren M., deSimone P., et al. Methods for detection of left ventricular hypertrophy application to hypertensive heart disease . Eur Heart J. 14:1993;8-15.
17. Yamamoto K., Burnett J.C. Jr, Jougasaki M., et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 26:1996;988-994.
18. Ambler S.K., Leite M.F. Regulation of atrial natriuretic peptide secretion by alpha 1-adrenergic receptors the role of different second messenger pathways . J Mol Cell Cardiol. 26:1994;391-402.
19. Knowlton K.U., Michel M.C., Itani M., et al. The alpha 1A-adrenergic receptor subtype mediates biochemical, molecular, and morphologic features of cultured myocardial cell hypertrophy. J Biol Chem. 268:1993;15374-15380.
20. Schiebinger R.J., Parr H.G., Cragoe E.J. Calcium its role in alpha 1-adrenergic stimulation of atrial natriuretic peptide secretion . Endocrinology. 130:1992;1017-1023.
21. Ardati A., Nemer M. A nuclear pathway for alpha 1-adrenergic receptor signaling in cardiac cells. Embo J. 12:1993;5131-5139.
22. Hanford D.S., Glembotski C.C. Stabilization of the B-type natriuretic peptide mRNA in cardiac myocytes by alpha-adrenergic receptor activation potential roles for protein kinase C and mitogen-activated protein kinase . Mol Endocrinol. 10:1996;1719-1727.
23. Yoshimura M., Yasue H., Morita E., et al. Hemodynamic, renal and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 84:1991;1581-1588.
24. Clarkson P.B.M., Wheeldon N.M., Macleod C., et al. Brain natriuretic peptide effect on left ventricular filling patterns in healthy subjects . Cli Sci. 88:1995;159-164.
25. Marcus L., Hart D., Packer M., et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. Circulation. 94:1996;3184-3189.
26. Burnett J.C.J., Granger J.P., Opgenorth T.J. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol. 247:1984;F863-F866.
27. Kawaguchi H., Sawa H., Yasuda H. Rapid communication effect of atrial natriuretic factor on angiotensin converting enzyme . J Mol Cell Cardiol. 21:1989;959-961.
28. Wada A., Tsutamoto T., Maeda Y., et al. Endogenous atrial natriuretic peptide inhibits endothelin-1 secretion in dogs with severe congestive heart failure. Am J Physiol. 270:1996;H1819-H1824.
29. Itoh H., Pratt R.E., Dzau V.J. Interaction of atrial natriuretic polypeptide and angiotensin II on protooncogene expression and vascular cell growth. Biochem Biophys Res Comm. 176:1991;1601-1609.
30. Cao L., Gardner D.G. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 25:1995;227-234.
31. Edwards B.S., Ackermann D.M., Lee M.E., et al. Identification of atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive heart failure. J Clin Invest. 81:1988;82-86.
32. Yasue H., Obata S., Okamura K., et al. Increased secretion of atrial natriuretic polypeptide (ANP) from the left ventricle in patients with dilated cardiomyopathy. J Clin Invest. 83:1989;46-51.
33. Yasue H., Yoshimura M., Sumida H., et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 90:1994;195-203.
34. Kohno M., Horio T., Yokokawa K., et al. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor . Am J Med. 98:1995;257-265.